The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.
After Moderna/Merck & Co’s December splash, full data from Keynote-942 stand up to scrutiny.
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
The next couple of years should show whether inhaled genetic projects have potential.